NASDAQ:KOD Kodiak Sciences (KOD) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free KOD Stock Alerts $2.81 +0.05 (+1.81%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$2.69▼$2.8750-Day Range$2.76▼$4.4852-Week Range$1.37▼$9.32Volume194,133 shsAverage Volume349,263 shsMarket Capitalization$147.61 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Kodiak Sciences alerts: Email Address Kodiak Sciences MarketRank™ Stock AnalysisAnalyst RatingReduce1.71 Rating ScoreUpside/Downside95.7% Upside$5.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.49Based on 9 Articles This WeekInsider TradingSelling Shares$4,549 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.55) to ($3.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.00 out of 5 starsMedical Sector348th out of 915 stocksBiological Products, Except Diagnostic Industry50th out of 152 stocks 2.9 Analyst's Opinion Consensus RatingKodiak Sciences has received a consensus rating of Reduce. The company's average rating score is 1.71, and is based on 1 buy rating, 3 hold ratings, and 3 sell ratings.Amount of Analyst CoverageKodiak Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Kodiak Sciences' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for KOD. Previous Next 0.0 Dividend Strength Dividend YieldKodiak Sciences does not currently pay a dividend.Dividend GrowthKodiak Sciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKodiak Sciences has received a 73.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Kodiak Sciences is -0.87. Previous Next 1.9 News and Social Media Coverage News SentimentKodiak Sciences has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Kodiak Sciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for KOD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kodiak Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,549.00 in company stock.Percentage Held by Insiders45.30% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kodiak Sciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kodiak Sciences are expected to grow in the coming year, from ($3.55) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kodiak Sciences is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kodiak Sciences is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKodiak Sciences has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kodiak Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Kodiak Sciences Stock (NASDAQ:KOD)Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Read More KOD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KOD Stock News HeadlinesJune 15 at 5:20 AM | americanbankingnews.comKodiak Sciences Inc. (NASDAQ:KOD) Given Average Rating of "Reduce" by AnalystsJune 12 at 3:20 AM | americanbankingnews.comCritical Contrast: Kodiak Sciences (NASDAQ:KOD) & Caribou Biosciences (NASDAQ:CRBU)June 11, 2024 | americanbankingnews.comZacks Research Equities Analysts Lift Earnings Estimates for Kodiak Sciences Inc. (NASDAQ:KOD)May 29, 2024 | prnewswire.comKodiak Sciences to Present at Upcoming Investor and Clinical ConferencesMay 17, 2024 | finanznachrichten.deKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial ResultsMay 16, 2024 | investing.comKodiak Sciences (KOD) Earnings Dates & ReportsMay 16, 2024 | finanznachrichten.deKodiak Sciences Inc.: Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic RetinopathyMay 16, 2024 | investorplace.comKOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024May 15, 2024 | prnewswire.comKodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial ResultsMay 13, 2024 | prnewswire.comKodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic RetinopathyMay 2, 2024 | prnewswire.comKodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) PlatformApril 30, 2024 | msn.comFlorida officials monitor over 30% increase in wildlife callsApril 29, 2024 | msn.comTractor-trailers with no one aboard? The future is near for self-driving trucks on US roads.April 27, 2024 | investing.comKodiak Sciences Inc (KOD)April 26, 2024 | msn.comReport portrays mixed picture of Alaska’s huge seafood industryApril 26, 2024 | msn.comHow the Great Alaska Earthquake Shook Up ScienceApril 17, 2024 | msn.comKodiak Sciences (KOD) Price Target Increased by 11.84% to 4.34April 11, 2024 | finance.yahoo.comWill Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely?April 3, 2024 | yahoo.comAlaska schools could buckle down on civicsMarch 30, 2024 | msn.comAlaska Legislature boosts allowable payments from fund that covers fishers’ crew medical costsMarch 30, 2024 | seekingalpha.comKodiak Sciences Inc. (KOD) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | markets.businessinsider.comBarclays Sticks to Their Sell Rating for Kodiak Sciences (KOD)March 29, 2024 | finance.yahoo.comQ4 2023 Kodiak Sciences Inc Earnings CallMarch 29, 2024 | theguardian.comSurge of new US-led oil and gas activity threatens to wreck Paris climate goalsMarch 28, 2024 | yahoo.comAlutiiq museum in Kodiak celebrates the past to connect with the futureSee More Headlines Receive KOD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/15/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:KOD CUSIPN/A CIK1468748 Webkodiak.com Phone(650) 281-0850FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$12.00 Low Stock Price Target$2.00 Potential Upside/Downside+95.7%Consensus RatingReduce Rating Score (0-4)1.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-260,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.11% Return on Assets-45.38% Debt Debt-to-Equity RatioN/A Current Ratio10.12 Quick Ratio10.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.07 per share Price / Book0.55Miscellaneous Outstanding Shares52,530,000Free Float28,737,000Market Cap$147.61 million OptionableOptionable Beta2.43 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Victor Perlroth M.D. (Age 51)Co-Founder, Chairman, CEO & President Comp: $1.08MMr. John A. Borgeson CPA (Age 62)M.B.A., Senior VP, CFO & Secretary Comp: $667.52kDr. Michael S. Louie Ph.D.Senior VP of Digital Transformation & Chief Information OfficerDr. Hong Liang (Age 52)Senior Vice President of Discovery Medicine Comp: $300.71kDr. Stephen Raillard Ph.D.Senior Vice President of Chemical Development & ManufacturingMs. Almas Qudrat M.Sc.Senior Vice President of Quality OperationsDr. J. Pablo Velazquez-Martin M.D.Senior VP of Clinical Research & DevelopmentTracy ChienVP & Corporate ControllerMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSLexeo TherapeuticsNASDAQ:LXEOValnevaNASDAQ:VALNCabaletta BioNASDAQ:CABAReplimune GroupNASDAQ:REPLView All CompetitorsInsiders & InstitutionsJohn A BorgesonSold 1,558 sharesTotal: $4,549.36 ($2.92/share)Ikarian Capital LLCBought 63,705 shares on 5/17/2024Ownership: 0.907%Jacobs Levy Equity Management Inc.Sold 198,025 shares on 5/16/2024Ownership: 1.001%Nan Fung Group Holdings LtdBought 12,300 shares on 5/14/2024Ownership: 0.061%Acadian Asset Management LLCSold 185,412 shares on 5/10/2024Ownership: 3.280%View All Insider TransactionsView All Institutional Transactions KOD Stock Analysis - Frequently Asked Questions Should I buy or sell Kodiak Sciences stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 3 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" KOD shares. View KOD analyst ratings or view top-rated stocks. What is Kodiak Sciences' stock price target for 2024? 7 brokers have issued 12 month price objectives for Kodiak Sciences' stock. Their KOD share price targets range from $2.00 to $12.00. On average, they expect the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 95.7% from the stock's current price. View analysts price targets for KOD or view top-rated stocks among Wall Street analysts. How have KOD shares performed in 2024? Kodiak Sciences' stock was trading at $3.04 on January 1st, 2024. Since then, KOD shares have decreased by 7.6% and is now trading at $2.81. View the best growth stocks for 2024 here. When is Kodiak Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our KOD earnings forecast. How were Kodiak Sciences' earnings last quarter? Kodiak Sciences Inc. (NASDAQ:KOD) released its earnings results on Wednesday, May, 15th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.27. What other stocks do shareholders of Kodiak Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Quest Diagnostics (DGX), Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and When did Kodiak Sciences IPO? Kodiak Sciences (KOD) raised $126 million in an IPO on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers. Who are Kodiak Sciences' major shareholders? Kodiak Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (3.28%), Vanguard Group Inc. (3.15%), Jacobs Levy Equity Management Inc. (1.00%), Ikarian Capital LLC (0.91%), Los Angeles Capital Management LLC (0.25%) and Sei Investments Co. (0.22%). Insiders that own company stock include Bros Advisors Lp Baker, Jason Ehrlich, John A Borgeson and Victor Perlroth. View institutional ownership trends. How do I buy shares of Kodiak Sciences? Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KOD) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.